Table 2.

Number and percent of subjects by category of clinical response at six months, by study arm

Clinical responseDrugPlacebo
CR2 (4.6%)2 (4.4%)
PR10 (23.3%)12 (26.1%)
Stable disease27 (62.8%)26 (56.5%)
Disease progression4 (9.3%)6 (13%)
Total43 (100%)46 (100%)

NOTE: CR: 100% reduction in total lesion areas. PR: atleast a 50% reduction, but not complete resolution, of total lesion areas. Stable disease: disease progression: FET P > 0.90